A privately-held neonatology pharmaceutical company, ONY Biotech is a leader in the creation of critically important products for the treatment of premature infants. We innovate with a singular purpose: to improve outcomes for premature babies and their families.
As a USA-born neonatology biotech, we take pride in the work we do delivering treatments that serve families here in the United States and around the world. ONY Biotech’s primary commercial product, Infasurf® (calfactant), helps prevent and treat respiratory distress syndrome in newborns. In keeping with our commitment to bring innovative neonatal therapies for unmet medical needs to market, a pivotal trial for the aerosolization of Infasurf® (calfactant) was recently completed.